A Paradigm Shift
in the Fight Against Brucellosis
Brucellosis significantly impacts poor livestock keepers in developing regions. Brucella Green Vac's BGV1, the first vaccine in over 60 years, addresses the limitations of Rev-1 by being safe for animals, not interfering with diagnostics, having low human transmissibility, and being treatable with standard antibiotics. BGV1 is a strong candidate to replace the outdated vaccine.
Great Interest and Successful Funding
To speed up the development of BGV1 and market launch the new vaccine into the market, Brucella Green Vac contacted Nordic Innovators to receive support for developing funding applications for EU programmes. We successfully collaborated on two projects, the former Horizon2020 and EIC Accelerator and received grants from both programmes.
This funding will enable, for the first time, mass vaccination of any animal at any time. This is a radical paradigm shift in Brucellosis control and eradication. The reduction of outbreaks and infection rate in animals will generate €3.81bn in cumulative economic benefits for users by 2028 by evading unnecessary diagnostics costs and losses caused by the infection.
The Difference the Funding Makes
"Recently, we have had the pleasure of obtaining financing of just over EUR 2 million on the first call for the EIC Accelerator Pilot - Horizon Europe programme. It has been a great experience since a total of 1700 applications were submitted of which only 5 Spanish proposals have been funded.
After signing the Grant Agreement with the European Commission, we were able to open the new office at the CEIN facilities in Pamplona hiring 4 researchers (2 PhDs and 2 predoctorals), with 2 other contracts in progress. The main objective of the project is to carry out the production of our new generation BGV1 vaccine and complete the efficacy tests against virulent infection by Brucella melitensis in sheep, which, together with the safety results obtained, will allow us to access the prize for Phase 2 of the competition promoted by the World Bank through AGResults, of great international impact. This competition awards prizes of up to 30 million dollars, which highlights the importance of finding new vaccines against animal brucellosis that solve the many and important drawbacks of classical vaccines. This is a necessary measure to combat this zoonosis, with a very high prevalence in the developing continents, being one of the health problems with the greatest economic impact on the planet."
"We greatly appreciate the support received by the Nordic Innovators’ consulting team. They have been quick to capture our own very specific needs from the start and come up with a very high-quality proposal for the European Commission." Ignacio Grilló, Director
